Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at Friday's sessions of the 2012 San Antonio Breast Cancer Symposium, including the HERA and PHARE trials of trastuzumab (Herceptin); bevacizumab's (Avastin) failure to move the needle in new data from the LEA and BEATRICE trials; and what the CLEOPATRA trial will mean for biomarker studies in clinical practice.